Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.71 |
| ▸ | CES1 | P23141 | 2/20 | 0.71 |
| ▸ | TERT | O14746 | 3/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.63 |
| ▸ | PPARG | P37231 | 3/20 | 0.63 |
| ▸ | PPARD | Q03181 | 3/20 | 0.63 |
| ▸ | PPARA | Q07869 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | FABP4 | P15090 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836005 | 1.00 | FAAH (0.71) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL22525273 | 1.00 | FAAH (0.71) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL22525183 | 1.00 | FAAH (0.71) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL25835999 | 1.00 | FAAH (0.71) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL25834781 | 1.00 | FAAH (0.71) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL23772133 | 1.00 | FAAH (0.71) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL20968838 | 0.95 | ALDH1A1 (0.67) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL20968796 | 0.93 | ALDH1A1 (0.68) | FAAHCES1PPARGPPARDPPARA | |
| SCHEMBL15821310 | 0.92 | FAAH (0.61) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL26054659 | 0.90 | FAAH (0.58) | FAAHCES1TERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357140-A1 | TES-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357140-A1 | TES-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210251864-A1 | ECO EMULSIFIER | SYMRISE AG (DE) | 2021-08-19 | — | — | US | disclosed |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-22 | — | — | US | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| US-20170224838-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-08-10 | — | — | US | disclosed |
| US-9629922-B2 | Nanoparticle-based tumor-targeted drug delivery | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-25 | — | — | US | disclosed |
| US-9616137-B2 | Nanoparticle-based tumor-targeted drug delivery | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20120058177-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | THE SCRIPPS RESEARCH INSTITUTE | 2012-03-08 | — | — | US | disclosed |
| US-20090163705-A1 | CATIONIC LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224838-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | LGMN, LAMP1, LNPEP | FAAH 1664/4885CES1 1632/4885TERT 4090/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | FAAH 2901/4885CES1 505/4885TERT 4567/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | FAAH 162/4885CES1 1237/4885TERT 272/4885 |
| US-20120058177-A1 | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY | LGMN, LNPEP, CLTA | FAAH 2415/4885CES1 1833/4885TERT 4520/4885 |
| US-20210251864-A1 | ECO EMULSIFIER | ECHS1, CS, ELOVL1 | FAAH 526/4885CES1 45/4885TERT 4017/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | FAAH 1225/4885CES1 57/4885TERT 2014/4885 |
| US-20230357140-A1 | TES-BASED CATIONIC LIPIDS | CETP, NPC1L1, NPC1 | FAAH 3353/4885CES1 47/4885TERT 1443/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | FAAH 4742/4885CES1 1301/4885TERT 4796/4885 |
| US-20090163705-A1 | CATIONIC LIPIDS | CETP, SGMS1, SGMS2 | FAAH 1286/4885CES1 678/4885TERT 4494/4885 |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | FAAH 163/4885CES1 1238/4885TERT 248/4885 |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | FAAH 4643/4885CES1 3419/4885TERT 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.